📇 Rhumatologue · EPAGNY METZ TESSY · (74) · Salarié

M MATTHIEU DEBRAY

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
43 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
131.5 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 EPAGNY METZ TESSY (74)SalariéRPPS 10003111456

3 publications sur 5 ans

📊 Reconnaissance scientifique : 7/100📝 14 articles publiés🇫🇷 Publications académiques françaises (4)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

The New England journal of medicine · 2018

📚 395 citations🎯 RCR 18.18Top 1% NIH🔓 Open Access📄 PDF gratuit ↗

Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis

The European respiratory journal · 2017

📚 186 citations🎯 RCR 7.39Top 4% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Despite its high prevalence and mortality, little is known about the pathogenesis of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Given that familial pulmonary fibrosis (FPF) and RA-ILD frequently share the usual pattern of interstitial pneumonia and common environmental risk factors, we hypothesised that the two diseases might share additional risk factors, including FPF-linked genes. Our aim was to identify coding mutations of FPF-risk genes associated with RA-ILD.We used whole exome sequencing (WES), followed by restricted analysis of a discrete number of FPF-linked genes and performed a burden test to assess the excess number of mutations in RA-ILD patients compared to controls.Among the 101 RA-ILD patients included, 12 (11.9%) had 13 WES-identified heterozygous mutations in theTERT,RTEL1,PARNorSFTPCcoding regions.The burden test, based on 81 RA-ILD patients and 1010 controls of European ancestry, revealed an excess ofTERT,RTEL1,PARNorSFTPCmutations in RA-ILD patients (OR 3.17, 95% CI 1.53–6.12; p=9.45×10−4). Telomeres were shorter in RA-ILD patients with aTERT,RTEL1orPARNmutation than in controls (p=2.87×10−2).Our results support the contribution of FPF-linked genes to RA-ILD susceptibility.

Methotrexate and rheumatoid arthritis associated interstitial lung disease

The European respiratory journal · 2021

📚 170 citations🎯 RCR 14.58Top 1% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Question addressed by the studyMethotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA. Whether MTX exposure increases the risk of ILD in patients with RA is disputed. We aimed to evaluate the association of prior MTX use with development of RA-ILD.MethodsThrough a case–control study design with discovery and international replication samples, we examined the association of MTX exposure with ILD in 410 patients with chronic fibrotic ILD associated with RA (RA-ILD) and 673 patients with RA without ILD. Estimates were pooled over the different samples using meta-analysis techniques.ResultsAnalysis of the discovery sample revealed an inverse relationship between MTX exposure and RA-ILD (adjusted OR 0.46, 95% CI 0.24–0.90; p=0.022), which was confirmed in the replication samples (pooled adjusted OR 0.39, 95% CI 0.19–0.79; p=0.009). The combined estimate using both the derivation and validation samples revealed an adjusted OR of 0.43 (95% CI 0.26–0.69; p=0.0006). MTX ever-users were less frequent among patients with RA-ILD compared to those without ILD, irrespective of chest high-resolution computed tomography pattern. In patients with RA-ILD, ILD detection was significantly delayed in MTX ever-users compared to never-users (11.4±10.4 years and 4.0±7.4 years, respectively; p<0.001).Answer to the questionOur results suggest that MTX use is not associated with an increased risk of RA-ILD in patients with RA, and that ILD was detected later in MTX-treated patients.

Cookies & analyse de trafic

M MATTHIEU DEBRAY

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (43) — classées par pathologie

Transversal22

Sjögren6

Gériatrie5

Essai clinique3

csDMARDs2

Lupus2

Biomarqueurs / Auto-Ac1

Génétique1

Revue générale1

Vascularites1

Datasets & protocoles partagés

Partager cette fiche